Results of a phase 3 randomized trial found that daily treatment with high-dose rifapentine for tuberculosis (TB) infection decreased efavirenz clearance and achieved therapeutic targets among patients coinfected with HIV receiving efavirenz-based antiretroviral therapy (ART). These findings were published in Clinical Infectious Diseases.